Introduction: Hypermutable Pseudomonas aeruginosa (HYPa)strains are frequently associated with chronic respiratory infections in patients with cystic fibrosis leading to increased morbidity and mortality. HYPa have increased mutation rates resulting in multidrug-resistance and treatment failure. Aims: To evaluate bacterial killing and resistance suppression of clinically relevant meropenem (MER) and tobramycin (TOB) dosage regimens against two clinical […]
Mechanism-based modelling of meropenem plus tobramycin combination regimens against clinical hypermutable Pseudomonas aeruginosa in the hollow-fibre infection model
January 10, 2021
Authors Akosua A. Agyeman (1), Rajbharan Yadav (1), Kate E. Rogers (1), Vanessa E. Rees (1), Yuling Huang (1), Anton Y. Peleg (2), John D. Boyce (1), Antonio Oliver (3), Phillip J. Bergen (1), Beom Soo Shin (4), Roger L. Nation (1), Cornelia B. Landersdorfer (1)
Affiliations 1. Pharmacy and Pharmaceutical Sciences and 2. Microbiology Monash University, Melbourne, Australia, 3. Hospital Universitario Son Espases, Palma de Mallorca, Spain; 4. School of Pharmacy, Sungkyunkwan University, Korea.
Presentation type Poster
Presenters Akosua A Agyeman
Attachments
